A quiet crisis is unfolding within the National Institutes of Health, the world’s leading public funder of biomedical research. Since the beginning of a recent presidential term, thousands of dedicated scientists have departed, leaving a void that many fear will jeopardize the nation’s health.
These weren’t just any researchers; they were pioneers in critical fields – individuals who dedicated their lives to unraveling the mysteries of cancer, combating debilitating tick-borne illnesses, and preventing the devastating consequences of tobacco use. Their exodus represents a significant loss of expertise and momentum.
Conversations with six former NIH scientists revealed a common thread: a sense of disillusionment stemming from a period of upheaval. They spoke of vital work left unfinished, and a growing concern that the nation’s ability to respond to future health crises is being severely undermined.
“People are going to get hurt,” warned Sylvia Chou, a scientist who spent over fifteen years at the National Cancer Institute before leaving earlier this year. “There’s going to be a lot more health challenges and even deaths, because we need science in order to help people get healthy.”
The NIH is a vast network, comprised of 27 institutes and centers, each focused on a unique area of medical research. From cancer and infectious diseases to Alzheimer’s and heart disease, the NIH touches nearly every aspect of human health.
For decades, the NIH has enjoyed bipartisan support in Washington, with lawmakers consistently increasing its funding. Even recently, Congress defied proposals to drastically cut the agency’s budget, recognizing its vital role in safeguarding public health.
Despite this financial backing, a troubling pattern emerged. Actions taken to restrict certain research areas and the perceived targeting of scientists deemed disloyal have had a chilling effect. The NIH workforce now stands at its lowest level in at least two decades, numbering around 17,100.
Scientists described a growing list of obstacles that drove them to seek opportunities elsewhere. These included frustrating delays in acquiring essential research equipment, the abrupt termination of funding for critical projects, and the denial of travel authorizations needed to collaborate with colleagues and present findings.
The impact wasn’t limited to research areas that clashed with the administration’s priorities. Even projects aligned with stated goals suffered, raising serious questions about the NIH’s ability to fulfill its core mission: to enhance health, lengthen life, and reduce illness.
“It’s clear when someone comes out with a drug and now you’ve just cured a disease,” explained Daniel Dulebohn, a researcher who dedicated nearly two decades to infectious disease research. “But you never know which ones could have been cured. We don’t know what we’ve lost.”
Dulebohn, who left the NIH’s infectious disease institute last year, is now contemplating leaving the scientific field altogether, a stark illustration of the profound impact this period is having on the nation’s scientific talent.
